0.6876

1.42% 0.0096

After Hours: .70 0.0124 +1.80%

Seres Therapeutics Inc (MCRB)

Overview News Price History Option Chain Financials Discussions Forecast

Seres Therapeutics Inc stock is traded at $0.6876, with a volume of 973.51K. It is up +1.42% in the last 24 hours and down -8.16% over the past month. Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.

Previous Close:

$0.678

Open:

$0.66

24h Volume:

973.51K

Relative Volume:

0.79

Market Cap:

$119.89M

Revenue:

$123.24M

Net Income/Loss:

$136.00K

P/E Ratio:

-34.38

EPS:

-0.02

Net Cash Flow:

$-148.99M

1W Performance:

-8.95%

1M Performance:

-8.16%

6M Performance:

-17.87%

1Y Performance:

-5.24%

1-Day Range:

$0.66

$0.729

1-Week Range:

$0.66

$0.7576

52-Week Range:

$0.54

$1.53

Seres Therapeutics Inc Stock (MCRB) Company Profile

Name

Seres Therapeutics Inc

Sector

Healthcare (1182)

Industry

Biotechnology (678)

Phone

617 945 9626

Address

200 SIDNEY STREET, CAMBRIDGE, MA

Employee

103

Twitter

@SeresTX

Next Earnings Date

2024-10-31

Latest SEC Filings

MCRB's Discussions on Twitter

Compare MCRB with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MCRB Seres Therapeutics Inc	0.6876	119.89M	123.24M	136.00K	-148.99M	-0.02
VRTX Vertex Pharmaceuticals Inc	484.01	124.29B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	610.64	68.39B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	590.06	35.99B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	262.16	33.93B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	264.32	28.47B	3.81B	-644.79M	-669.77M	-6.24

Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-24-24	Downgrade	JP Morgan	Neutral → Underweight
Jun-26-23	Resumed	Oppenheimer	Outperform
Apr-21-23	Initiated	JP Morgan	Neutral
Jul-23-21	Downgrade	Goldman	Neutral → Sell
May-18-21	Resumed	Goldman	Neutral
Mar-05-21	Upgrade	Chardan Capital Markets	Neutral → Buy
Sep-18-20	Downgrade	Chardan Capital Markets	Buy → Neutral
Aug-18-20	Initiated	Piper Sandler	Overweight
Aug-11-20	Reiterated	H.C. Wainwright	Buy
Aug-11-20	Upgrade	Jefferies	Hold → Buy
Apr-30-19	Initiated	Jefferies	Hold
Oct-22-18	Initiated	Chardan Capital Markets	Buy
Oct-13-17	Initiated	Oppenheimer	Outperform
Aug-04-17	Reiterated	H.C. Wainwright	Buy
Feb-01-17	Reiterated	FBR & Co.	Outperform
Aug-12-16	Reiterated	FBR Capital	Outperform
Aug-01-16	Downgrade	BofA/Merrill	Buy → Neutral
Aug-01-16	Reiterated	H.C. Wainwright	Buy
Jul-29-16	Resumed	H.C. Wainwright	Buy
Mar-30-16	Initiated	FBR Capital	Outperform
Mar-03-16	Initiated	Guggenheim	Buy
Jan-25-16	Initiated	H.C. Wainwright	Buy
Oct-22-15	Upgrade	BofA/Merrill	Neutral → Buy
Jul-22-15	Initiated	Canaccord Genuity	Buy
Jul-21-15	Initiated	Goldman	Neutral
Jul-21-15	Initiated	Leerink Partners	Outperform

View All

Seres Therapeutics Inc Stock (MCRB) Latest News

12:46 PM

INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Regarding Possible Violations of Federal Securities Laws by Certain Officers and Directors of Seres Therapeutics, Inc.MCRB - ACCESS Newswire

12:46 PM

Apr 01, 2025

Charles Schwab Investment Management Inc. Purchases 117,107 Shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) - Defense World

Apr 01, 2025

Mar 28, 2025

FY2025 Earnings Forecast for MCRB Issued By Chardan Capital - Defense World

Mar 28, 2025

Avantax Advisory Services Inc. Increases Stake in Seres Therapeutics, Inc. (NASDAQ:MCRB) - Defense World

Mar 28, 2025

Mar 23, 2025

Seres Therapeutics (NASDAQ:MCRB) Given "Buy" Rating at Chardan Capital - MarketBeat

Mar 23, 2025

Mar 22, 2025

Chardan Capital Reiterates Buy Rating for Seres Therapeutics (NASDAQ:MCRB) - Defense World

Mar 22, 2025

Mar 21, 2025

Microbiome Disease Pipeline Insight 2025: Over 180 Drugs in Development Across 140+ Companies - GlobeNewswire Inc.

Mar 21, 2025

Mar 20, 2025

Petri Dish: Flagship spinout Ampersand raises $65M, Seres medical chief lands new role - The Business Journals

Mar 20, 2025

Mar 17, 2025

Seres Therapeutics, Inc. (NASDAQ:MCRB) Receives $4.00 Consensus Target Price from Brokerages - Defense World

Mar 17, 2025

Mar 16, 2025

The Goldman Sachs Group Issues Pessimistic Forecast for Seres Therapeutics (NASDAQ:MCRB) Stock Price - Defense World

Mar 16, 2025

Mar 15, 2025

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Mar 15, 2025

Mar 14, 2025

Seres Therapeutics, Inc. (NASDAQ:MCRB) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 14, 2025

Seres Therapeutics, Inc. (NASDAQ:MCRB): Are Analysts Optimistic? - Yahoo Finance

Mar 14, 2025

Earnings call transcript: Seres Therapeutics Q4 2024 financial results disappoint By Investing.com - Investing.com South Africa

Mar 14, 2025

Seres Therapeutics Advances SER-155 Program with FDA Support - TipRanks

Mar 14, 2025